Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Consolidated Statements of Operations
Collaboration revenues		$ 641,140		$ 1,708,738
Operating expenses:
Research and development	$ 4,383,214	5,935,884	$ 10,230,516	12,007,406
General and administrative	1,957,175	1,849,158	4,293,899	4,753,146
Impairment of property and equipment	423,328	561,735	423,328	2,911,138
Total operating expenses	6,763,717	8,346,777	14,947,743	19,671,690
Loss from operations	(6,763,717)	(7,705,637)	(14,947,743)	(17,962,952)
Interest expense, net	696,151	1,053,877	1,293,816	2,174,726
Loss on extinguishment of debt		183,554	8,060,580	183,554
Change in fair value of redemption feature	(1,759,037)		(1,796,982)
Change in fair value of warrant liability	(764)	1,301,728	(202,142)	(334,592)
Net loss	(5,700,067)	(10,244,796)	(22,303,015)	(19,986,640)
Beneficial conversion feature upon issuance of Series A-1 convertible preferred stock		(61,365)		(61,365)
Series A-1 convertible preferred stock dividends and related settlement		(154,271)	(166,133)	(304,779)
Deemed dividend upon modification of warrants	(1,431,406)	(829,530)	(3,140,009)	(829,530)
Deemed dividend upon amendment of the terms of the Series A-1 convertible preferred stock	(10,328,118)		(10,328,118)
Net loss attributable to common stockholders	$ (17,459,591)	$ (11,289,962)	$ (35,937,275)	$ (21,182,314)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.36)	$ (0.98)	$ (0.93)	$ (1.98)
Weighted average shares outstanding, basic and diluted (in shares)	47,895,771	11,529,033	38,849,364	10,677,020